Financial Performance - Total revenue reached $1.2 billion[12] - Systemwide comparable sales increased by 12.7%[12] - Adjusted EBITDA was $201.1 million with a 16.9% margin[12] - Net income amounted to $150.4 million, or $0.71 per share[12] - Net income was boosted by a $125.2 million net benefit from a federal tax credit in Brazil[14] Digital Sales & Loyalty - Digital sales contributed approximately 61% of total sales[12] - Loyalty program registered members increased to 23.6 million[22] Divisional Performance - Brazil's revenue was $452.6 million[24] - NOLAD (Northern Latin America Division) revenue was $328.5 million[25] - SLAD (Southern Latin America Division) revenue was $411.8 million[25] Development & Capital Expenditure - Opened 22 restaurants during the quarter, with 19 being freestanding[12] - Capital expenditures totaled $75.8 million, including $44.2 million for new restaurant openings[17] Balance Sheet - Net debt stood at $474 million[43] - Leverage ratio is 1.2x[44]

Q3 2025 Performance - Total gold production reached 79,645 ounces, and total gold sold was 78,857 ounces[24] - The average realized gold price was $3,417 per ounce[32] - Operating cash flow was $113 million, or $0.34 per share[31] - The company reported a net income of $49.3 million, or $0.15 per share[31] - Adjusted earnings were $73.0 million, or $0.22 per share[31] - All-in sustaining costs (AISC) were $1,641 per ounce[30] Operations - Musselwhite milled 329,634 tonnes of ore with a gold grade of 5.87 g/t, producing 57,586 ounces of gold[24] - Camino Rojo stacked 2,793,951 tonnes of ore with a gold head grade of 0.40 g/t, producing 22,059 ounces of gold[24] South Railroad Project - An updated Feasibility Study is expected in Q4 2025[26] - Construction is expected to begin in mid-2026, with first gold production targeted for 2028[28] Guidance - The company updated its 2025 gold production guidance to 265,000 - 285,000 ounces[69]

Strong Core, Transformative Growth Investor Day 2025 November 12 Safe harbor statement Certain statements in this material, other than statements of historical or current fact, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova's plans, objectives, strategies, financial performance and outlook, trends, the amount and timi ...

The next phase of Vaca Muerta-driven growth VISTA ENERGY INVESTOR DAY NOVEMBER 12th, 2025 About projections and forward-looking statements 02 Additional information about Vista Energy, S.A.B. de C.V., a sociedad anónima bursátil de capital variable organized under the laws of Mexico (the "Company" or"Vista") can be found in the "Investors" section on the website at www.vistaenergy.com. This presentation does not constitute an offerto sell or a solicitation of any offerto buy any securities of the Company, i ...

Financial Performance - Q3 2025 revenues reached $15.3 million, a significant increase compared to $4.5 million in Q3 2024[25] - Year-to-date (YTD) revenues for 2025 totaled $42.4 million, approximately 2.3 times greater than the same period in 2024[8, 28] - Q3 2025 saw a cash burn of $14.0 million[8, 28] - Operating expenses were reduced to $18.1 million in Q3 2025, a 30% decrease from $26.0 million in Q3 2024[25] Business Development & Technology - A major commercial vehicle OEM selected Innoviz for series production of L4 autonomous class-8 semi trucks[7, 12, 29] - Innoviz has begun shipping InnovizTwo sensors for the OEM's data collection trucking fleet[12] - Innoviz is developing software modifications to address the OEM's unique vehicle integration requirements[12] - InnovizSMART-based perimeter security solution outperformed existing radar/camera systems in auditor testing[7, 16, 29] - Innoviz unveiled InnovizThree, designed for behind-the-windshield integration with a smaller form factor, better performance, and lower power consumption[8] Targets - The company is aiming for revenues between $50 million and $60 million[22] - The company is aiming for NRE Bookings between $30 million and $60 million[22]

Financial Performance & Guidance - The company expects approximately $340 million in revenues and adjusted EBITDA of approximately $250 million[9, 10] - The average cost of the four drydockings was approximately $5.6 million per vessel[19] - The company completed $355 million of new financing, releasing $94 million[27] - All-time high cash position of $479 million[27] Market Dynamics - Global LNG exports year-to-date 2025 amounted to 350 MT, a 3% increase year-over-year[33] - European LNG imports increased by 26% year-over-year, reaching 102.6 MT, while Asian imports decreased[33] - US LNG exports have seen strong growth, with Freeport exports up 32% year-over-year and Plaquemines seeing significant increases[36, 37] Fleet & Operations - All four drydockings were completed on time and on budget[14] - The average fleet age is 60 years as of November 2025[27] Newbuild & Scrapping Trends - Newbuild prices have stabilized at approximately $245 million, curbing new orders year-to-date[38, 42] - LNG vessel scrapping is at a new high in 2025[43]

Financial Performance & Outlook - Reported net sales increased by 8% to $468 million[18] - Adjusted operating income increased by 6% to $104 million[18] - Adjusted operating margin was 22.1%, a decrease of 50 bps[18] - Adjusted EPS increased by 6% to $1.94[18] - Free cash flow saw a significant increase of 144% to $100 million[18] - The company maintains a low-single-digit organic sales growth outlook for 2025[18, 19] Business Highlights - G1TM XR 2025 Edition SCBA received NFPA approval[19] - Strong performance continued in detection and industrial PPE during the third quarter[19] Strategic Focus - The company aims to be the leading provider of safety solutions[6] - The company is focused on driving profitable, above-market growth through its ACCELERATE strategy[20]

Investor Presentation Q3 2025 November 12, 2025 Forward Looking Statements This presentation contains historical information and forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the safe- harbor provisions of the Private Securities Litigation Reform Act of 1995 with respect to the business, financial condition and results of operations of Perion. The words "will," "believe," "expect," "intend," "plan," "should," "es ...

Financial Performance - Revenue was $1.69 billion, a decrease of 3% year-over-year[12, 51] - Non-IFRS Gross Margin increased by 130bps year-over-year to 26.0%[12] - Non-IFRS Earnings per Share was $0.41, flat year-over-year[12] - Adjusted free cash flow margin was approximately 27% in Q3 2025[17] End Market Analysis - Automotive revenue increased by 20% year-over-year to $306 million[42] - Communications Infrastructure and Data Center revenue increased by 32% year-over-year to $175 million[50] - Smart Mobile Devices revenue was $752 million, a decrease of 13% year-over-year[40] - Home and Industrial IoT revenue was $258 million, a decrease of 16% year-over-year[45] Key Strategic Initiatives - GF is expanding manufacturing capabilities at the Dresden site with a €1.1 billion investment, aiming to increase production capacity to over one million wafers per year by the end of 2028[30] - GF and Silicon Labs are expanding their partnership in the U.S., with GF manufacturing high-performance wireless SoCs in Malta, New York[26]

Financial Performance - AUCATZYL achieved net product sales of $21.1 million in Q3 2025[10] - Total revenue for Q3 2025 was $21.194 million[55] - Revenue for the nine months ended September 30, 2025, reached $51.0 million[11] - The company reported a total comprehensive loss of $84.9 million in Q3 2025[55] - As of September 30, 2025, the company's cash position was $367.4 million[56] AUCATZYL Launch and Market Access - AUCATZYL has been launched in the US, with strong initial execution in relapsed/refractory B-ALL (r/r B-ALL)[7] - The company has established 60 authorized treatment centers[14] - AUCATZYL has achieved patient access for over 90% of U S covered lives, exceeding initial expectations[14] - CAR T market share in relapsed/refractory disease in 2024 is approximately 15%[15] Obe-cel Expansion and Pipeline - The company is exploring the potential of obe-cel in new indications beyond adult B-ALL, including pediatric ALL, lupus nephritis, and multiple sclerosis[7] - In a Phase 1 study of obe-cel in Systemic Lupus Erythematosus (SLE), 83.3% (5/6) of patients achieved DORIS (Definition of Remission in SLE)[40] - In the SLE study, 50% (3/6) of patients achieved CRR (complete renal response)[40]